JavaScript NENÍ povolen !

Prosím povolte JavaScript.

* Zobrazit nápovědu

Reset

MeSH: azithromycin-aplikace a dávkování

67 záznamů v Medvik Filtry

Článek online

Trial of Three Rounds of Mass Azithromycin Administration for Yaws Eradication

John, Lucy N
Autor John, Lucy N From the National Department of Health, Aopi Centre (L.N.J., W.H.), the School of Medicine and Health Sciences, University of Papua New Guinea (L.N.J., O.M.), and the World Health Organization Representative Office in Papua New Guinea (J.K.W.), Port Moresby, the New Ireland Provincial Health Authority, Kavieng (M.S., E.J., E.M.), and Lihir Medical Center, International SOS, Lihir Island (R.K., O.M.) - all in Papua New Guinea the Infectious Diseases Department and Fight AIDS and Infectious Diseases Foundation, Hospital Universitari Germans Trias i Pujol (L.N.J., C.G.B., D.O., B.C., M.V.-M., O.M.), the Genomes for Life-Genomes of Catalonia Lab Group, Institute for Health Science Research Germans Trias i Pujol (I.G.-F.), and the IrsiCaixa AIDS Research Institute (B.C.), Badalona, the Barcelona Institute for Global Health, Faculty of Medicine, University of Barcelona (L.N.J.), and the Institute for Research in Biomedicine, Barcelona Institute of Science and Technology (I.G.-F.), Barcelona, and Universitat de Vic-Universitat Central de Catalunya, Vic (B.C., O.M.) - all in Spain the Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic (M. Medappa, P.P., D.Š.) the Parasites and Microbes Programme, Wellcome Sanger Institute, Hinxton (M.A.B.), and the Clinical Research Department, London School of Hygiene and Tropical Medicine, and the Hospital for Tropical Diseases, University College London Hospitals, London (M. Marks) - all in the United Kingdom the Department of Medicine, Division of Allergy and Infectious Diseases, and the Department of Global Health, University of Washington, Seattle (L.G.) and the Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston (E.Q.M.)
Beiras, Camila G
Autor Beiras, Camila G From the National Department of Health, Aopi Centre (L.N.J., W.H.), the School of Medicine and Health Sciences, University of Papua New Guinea (L.N.J., O.M.), and the World Health Organization Representative Office in Papua New Guinea (J.K.W.), Port Moresby, the New Ireland Provincial Health Authority, Kavieng (M.S., E.J., E.M.), and Lihir Medical Center, International SOS, Lihir Island (R.K., O.M.) - all in Papua New Guinea the Infectious Diseases Department and Fight AIDS and Infectious Diseases Foundation, Hospital Universitari Germans Trias i Pujol (L.N.J., C.G.B., D.O., B.C., M.V.-M., O.M.), the Genomes for Life-Genomes of Catalonia Lab Group, Institute for Health Science Research Germans Trias i Pujol (I.G.-F.), and the IrsiCaixa AIDS Research Institute (B.C.), Badalona, the Barcelona Institute for Global Health, Faculty of Medicine, University of Barcelona (L.N.J.), and the Institute for Research in Biomedicine, Barcelona Institute of Science and Technology (I.G.-F.), Barcelona, and Universitat de Vic-Universitat Central de Catalunya, Vic (B.C., O.M.) - all in Spain the Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic (M. Medappa, P.P., D.Š.) the Parasites and Microbes Programme, Wellcome Sanger Institute, Hinxton (M.A.B.), and the Clinical Research Department, London School of Hygiene and Tropical Medicine, and the Hospital for Tropical Diseases, University College London Hospitals, London (M. Marks) - all in the United Kingdom the Department of Medicine, Division of Allergy and Infectious Diseases, and the Department of Global Health, University of Washington, Seattle (L.G.) and the Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston (E.Q.M.)
Houinei, Wendy
Autor Houinei, Wendy From the National Department of Health, Aopi Centre (L.N.J., W.H.), the School of Medicine and Health Sciences, University of Papua New Guinea (L.N.J., O.M.), and the World Health Organization Representative Office in Papua New Guinea (J.K.W.), Port Moresby, the New Ireland Provincial Health Authority, Kavieng (M.S., E.J., E.M.), and Lihir Medical Center, International SOS, Lihir Island (R.K., O.M.) - all in Papua New Guinea the Infectious Diseases Department and Fight AIDS and Infectious Diseases Foundation, Hospital Universitari Germans Trias i Pujol (L.N.J., C.G.B., D.O., B.C., M.V.-M., O.M.), the Genomes for Life-Genomes of Catalonia Lab Group, Institute for Health Science Research Germans Trias i Pujol (I.G.-F.), and the IrsiCaixa AIDS Research Institute (B.C.), Badalona, the Barcelona Institute for Global Health, Faculty of Medicine, University of Barcelona (L.N.J.), and the Institute for Research in Biomedicine, Barcelona Institute of Science and Technology (I.G.-F.), Barcelona, and Universitat de Vic-Universitat Central de Catalunya, Vic (B.C., O.M.) - all in Spain the Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic (M. Medappa, P.P., D.Š.) the Parasites and Microbes Programme, Wellcome Sanger Institute, Hinxton (M.A.B.), and the Clinical Research Department, London School of Hygiene and Tropical Medicine, and the Hospital for Tropical Diseases, University College London Hospitals, London (M. Marks) - all in the United Kingdom the Department of Medicine, Division of Allergy and Infectious Diseases, and the Department of Global Health, University of Washington, Seattle (L.G.) and the Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston (E.Q.M.)
Medappa, Monica
Autor Medappa, Monica From the National Department of Health, Aopi Centre (L.N.J., W.H.), the School of Medicine and Health Sciences, University of Papua New Guinea (L.N.J., O.M.), and the World Health Organization Representative Office in Papua New Guinea (J.K.W.), Port Moresby, the New Ireland Provincial Health Authority, Kavieng (M.S., E.J., E.M.), and Lihir Medical Center, International SOS, Lihir Island (R.K., O.M.) - all in Papua New Guinea the Infectious Diseases Department and Fight AIDS and Infectious Diseases Foundation, Hospital Universitari Germans Trias i Pujol (L.N.J., C.G.B., D.O., B.C., M.V.-M., O.M.), the Genomes for Life-Genomes of Catalonia Lab Group, Institute for Health Science Research Germans Trias i Pujol (I.G.-F.), and the IrsiCaixa AIDS Research Institute (B.C.), Badalona, the Barcelona Institute for Global Health, Faculty of Medicine, University of Barcelona (L.N.J.), and the Institute for Research in Biomedicine, Barcelona Institute of Science and Technology (I.G.-F.), Barcelona, and Universitat de Vic-Universitat Central de Catalunya, Vic (B.C., O.M.) - all in Spain the Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic (M. Medappa, P.P., D.Š.) the Parasites and Microbes Programme, Wellcome Sanger Institute, Hinxton (M.A.B.), and the Clinical Research Department, London School of Hygiene and Tropical Medicine, and the Hospital for Tropical Diseases, University College London Hospitals, London (M. Marks) - all in the United Kingdom the Department of Medicine, Division of Allergy and Infectious Diseases, and the Department of Global Health, University of Washington, Seattle (L.G.) and the Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston (E.Q.M.)
Sabok, Maria
Autor Sabok, Maria From the National Department of Health, Aopi Centre (L.N.J., W.H.), the School of Medicine and Health Sciences, University of Papua New Guinea (L.N.J., O.M.), and the World Health Organization Representative Office in Papua New Guinea (J.K.W.), Port Moresby, the New Ireland Provincial Health Authority, Kavieng (M.S., E.J., E.M.), and Lihir Medical Center, International SOS, Lihir Island (R.K., O.M.) - all in Papua New Guinea the Infectious Diseases Department and Fight AIDS and Infectious Diseases Foundation, Hospital Universitari Germans Trias i Pujol (L.N.J., C.G.B., D.O., B.C., M.V.-M., O.M.), the Genomes for Life-Genomes of Catalonia Lab Group, Institute for Health Science Research Germans Trias i Pujol (I.G.-F.), and the IrsiCaixa AIDS Research Institute (B.C.), Badalona, the Barcelona Institute for Global Health, Faculty of Medicine, University of Barcelona (L.N.J.), and the Institute for Research in Biomedicine, Barcelona Institute of Science and Technology (I.G.-F.), Barcelona, and Universitat de Vic-Universitat Central de Catalunya, Vic (B.C., O.M.) - all in Spain the Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic (M. Medappa, P.P., D.Š.) the Parasites and Microbes Programme, Wellcome Sanger Institute, Hinxton (M.A.B.), and the Clinical Research Department, London School of Hygiene and Tropical Medicine, and the Hospital for Tropical Diseases, University College London Hospitals, London (M. Marks) - all in the United Kingdom the Department of Medicine, Division of Allergy and Infectious Diseases, and the Department of Global Health, University of Washington, Seattle (L.G.) and the Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston (E.Q.M.)
Kolmau, Reman
Autor Kolmau, Reman From the National Department of Health, Aopi Centre (L.N.J., W.H.), the School of Medicine and Health Sciences, University of Papua New Guinea (L.N.J., O.M.), and the World Health Organization Representative Office in Papua New Guinea (J.K.W.), Port Moresby, the New Ireland Provincial Health Authority, Kavieng (M.S., E.J., E.M.), and Lihir Medical Center, International SOS, Lihir Island (R.K., O.M.) - all in Papua New Guinea the Infectious Diseases Department and Fight AIDS and Infectious Diseases Foundation, Hospital Universitari Germans Trias i Pujol (L.N.J., C.G.B., D.O., B.C., M.V.-M., O.M.), the Genomes for Life-Genomes of Catalonia Lab Group, Institute for Health Science Research Germans Trias i Pujol (I.G.-F.), and the IrsiCaixa AIDS Research Institute (B.C.), Badalona, the Barcelona Institute for Global Health, Faculty of Medicine, University of Barcelona (L.N.J.), and the Institute for Research in Biomedicine, Barcelona Institute of Science and Technology (I.G.-F.), Barcelona, and Universitat de Vic-Universitat Central de Catalunya, Vic (B.C., O.M.) - all in Spain the Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic (M. Medappa, P.P., D.Š.) the Parasites and Microbes Programme, Wellcome Sanger Institute, Hinxton (M.A.B.), and the Clinical Research Department, London School of Hygiene and Tropical Medicine, and the Hospital for Tropical Diseases, University College London Hospitals, London (M. Marks) - all in the United Kingdom the Department of Medicine, Division of Allergy and Infectious Diseases, and the Department of Global Health, University of Washington, Seattle (L.G.) and the Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston (E.Q.M.)
Jonathan, Eunice
Autor Jonathan, Eunice From the National Department of Health, Aopi Centre (L.N.J., W.H.), the School of Medicine and Health Sciences, University of Papua New Guinea (L.N.J., O.M.), and the World Health Organization Representative Office in Papua New Guinea (J.K.W.), Port Moresby, the New Ireland Provincial Health Authority, Kavieng (M.S., E.J., E.M.), and Lihir Medical Center, International SOS, Lihir Island (R.K., O.M.) - all in Papua New Guinea the Infectious Diseases Department and Fight AIDS and Infectious Diseases Foundation, Hospital Universitari Germans Trias i Pujol (L.N.J., C.G.B., D.O., B.C., M.V.-M., O.M.), the Genomes for Life-Genomes of Catalonia Lab Group, Institute for Health Science Research Germans Trias i Pujol (I.G.-F.), and the IrsiCaixa AIDS Research Institute (B.C.), Badalona, the Barcelona Institute for Global Health, Faculty of Medicine, University of Barcelona (L.N.J.), and the Institute for Research in Biomedicine, Barcelona Institute of Science and Technology (I.G.-F.), Barcelona, and Universitat de Vic-Universitat Central de Catalunya, Vic (B.C., O.M.) - all in Spain the Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic (M. Medappa, P.P., D.Š.) the Parasites and Microbes Programme, Wellcome Sanger Institute, Hinxton (M.A.B.), and the Clinical Research Department, London School of Hygiene and Tropical Medicine, and the Hospital for Tropical Diseases, University College London Hospitals, London (M. Marks) - all in the United Kingdom the Department of Medicine, Division of Allergy and Infectious Diseases, and the Department of Global Health, University of Washington, Seattle (L.G.) and the Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston (E.Q.M.)
Maika, Edward
Autor Maika, Edward From the National Department of Health, Aopi Centre (L.N.J., W.H.), the School of Medicine and Health Sciences, University of Papua New Guinea (L.N.J., O.M.), and the World Health Organization Representative Office in Papua New Guinea (J.K.W.), Port Moresby, the New Ireland Provincial Health Authority, Kavieng (M.S., E.J., E.M.), and Lihir Medical Center, International SOS, Lihir Island (R.K., O.M.) - all in Papua New Guinea the Infectious Diseases Department and Fight AIDS and Infectious Diseases Foundation, Hospital Universitari Germans Trias i Pujol (L.N.J., C.G.B., D.O., B.C., M.V.-M., O.M.), the Genomes for Life-Genomes of Catalonia Lab Group, Institute for Health Science Research Germans Trias i Pujol (I.G.-F.), and the IrsiCaixa AIDS Research Institute (B.C.), Badalona, the Barcelona Institute for Global Health, Faculty of Medicine, University of Barcelona (L.N.J.), and the Institute for Research in Biomedicine, Barcelona Institute of Science and Technology (I.G.-F.), Barcelona, and Universitat de Vic-Universitat Central de Catalunya, Vic (B.C., O.M.) - all in Spain the Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic (M. Medappa, P.P., D.Š.) the Parasites and Microbes Programme, Wellcome Sanger Institute, Hinxton (M.A.B.), and the Clinical Research Department, London School of Hygiene and Tropical Medicine, and the Hospital for Tropical Diseases, University College London Hospitals, London (M. Marks) - all in the United Kingdom the Department of Medicine, Division of Allergy and Infectious Diseases, and the Department of Global Health, University of Washington, Seattle (L.G.) and the Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston (E.Q.M.)
Wangi, James K
Autor Wangi, James K From the National Department of Health, Aopi Centre (L.N.J., W.H.), the School of Medicine and Health Sciences, University of Papua New Guinea (L.N.J., O.M.), and the World Health Organization Representative Office in Papua New Guinea (J.K.W.), Port Moresby, the New Ireland Provincial Health Authority, Kavieng (M.S., E.J., E.M.), and Lihir Medical Center, International SOS, Lihir Island (R.K., O.M.) - all in Papua New Guinea the Infectious Diseases Department and Fight AIDS and Infectious Diseases Foundation, Hospital Universitari Germans Trias i Pujol (L.N.J., C.G.B., D.O., B.C., M.V.-M., O.M.), the Genomes for Life-Genomes of Catalonia Lab Group, Institute for Health Science Research Germans Trias i Pujol (I.G.-F.), and the IrsiCaixa AIDS Research Institute (B.C.), Badalona, the Barcelona Institute for Global Health, Faculty of Medicine, University of Barcelona (L.N.J.), and the Institute for Research in Biomedicine, Barcelona Institute of Science and Technology (I.G.-F.), Barcelona, and Universitat de Vic-Universitat Central de Catalunya, Vic (B.C., O.M.) - all in Spain the Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic (M. Medappa, P.P., D.Š.) the Parasites and Microbes Programme, Wellcome Sanger Institute, Hinxton (M.A.B.), and the Clinical Research Department, London School of Hygiene and Tropical Medicine, and the Hospital for Tropical Diseases, University College London Hospitals, London (M. Marks) - all in the United Kingdom the Department of Medicine, Division of Allergy and Infectious Diseases, and the Department of Global Health, University of Washington, Seattle (L.G.) and the Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston (E.Q.M.)
Pospíšilová, Petra
Autor Pospíšilová, Petra From the National Department of Health, Aopi Centre (L.N.J., W.H.), the School of Medicine and Health Sciences, University of Papua New Guinea (L.N.J., O.M.), and the World Health Organization Representative Office in Papua New Guinea (J.K.W.), Port Moresby, the New Ireland Provincial Health Authority, Kavieng (M.S., E.J., E.M.), and Lihir Medical Center, International SOS, Lihir Island (R.K., O.M.) - all in Papua New Guinea the Infectious Diseases Department and Fight AIDS and Infectious Diseases Foundation, Hospital Universitari Germans Trias i Pujol (L.N.J., C.G.B., D.O., B.C., M.V.-M., O.M.), the Genomes for Life-Genomes of Catalonia Lab Group, Institute for Health Science Research Germans Trias i Pujol (I.G.-F.), and the IrsiCaixa AIDS Research Institute (B.C.), Badalona, the Barcelona Institute for Global Health, Faculty of Medicine, University of Barcelona (L.N.J.), and the Institute for Research in Biomedicine, Barcelona Institute of Science and Technology (I.G.-F.), Barcelona, and Universitat de Vic-Universitat Central de Catalunya, Vic (B.C., O.M.) - all in Spain the Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic (M. Medappa, P.P., D.Š.) the Parasites and Microbes Programme, Wellcome Sanger Institute, Hinxton (M.A.B.), and the Clinical Research Department, London School of Hygiene and Tropical Medicine, and the Hospital for Tropical Diseases, University College London Hospitals, London (M. Marks) - all in the United Kingdom the Department of Medicine, Division of Allergy and Infectious Diseases, and the Department of Global Health, University of Washington, Seattle (L.G.) and the Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston (E.Q.M.)

The New England journal of medicine. 2022 ; 386 (1) : 47-56. [pub] 20220106

N Engl J Med
ISSN 1533-4406
Medvik
Zdroj

BACKGROUND: Treponema pallidum subspecies pertenue causes yaws. Strategies to better control, eliminate, and eradicate yaws are needed. METHODS: In an open-label, cluster-randomized, community-based trial conducted in a yaws-endemic area of Papua New Guinea, we randomly assigned 38 wards (i.e., clusters) to receive one round of mass administration of azithromycin followed by two rounds of target treatment of active cases (control group) or three rounds of mass administration of azithromycin (experimental group); round 1 was administered at baseline, round 2 at 6 months, and round 3 at 12 months. The coprimary end points were the prevalence of active cases of yaws, confirmed by polymerase-chain-reaction assay, in the entire trial population and the prevalence of latent yaws, confirmed by serologic testing, in a subgroup of asymptomatic children 1 to 15 years of age; prevalences were measured at 18 months, and the between-group differences were calculated. RESULTS: Of the 38 wards, 19 were randomly assigned to the control group (30,438 persons) and 19 to the experimental group (26,238 persons). A total of 24,848 doses of azithromycin were administered in the control group (22,033 were given to the participants at round 1 and 207 and 2608 were given to the participants with yaws-like lesions and their contacts, respectively, at rounds 2 and 3 [combined]), and 59,852 doses were administered in the experimental group. At 18 months, the prevalence of active yaws had decreased from 0.46% (102 of 22,033 persons) at baseline to 0.16% (47 of 29,954 persons) in the control group and from 0.43% (87 of 20,331 persons) at baseline to 0.04% (10 of 25,987 persons) in the experimental group (relative risk adjusted for clustering, 4.08; 95% confidence interval [CI], 1.90 to 8.76). The prevalence of other infectious ulcers decreased to a similar extent in the two treatment groups. The prevalence of latent yaws at 18 months was 6.54% (95% CI, 5.00 to 8.08) among 994 children in the control group and 3.28% (95% CI, 2.14 to 4.42) among 945 children in the experimental group (relative risk adjusted for clustering and age, 2.03; 95% CI, 1.12 to 3.70). Three cases of yaws with resistance to macrolides were found in the experimental group. CONCLUSIONS: The reduction in the community prevalence of yaws was greater with three rounds of mass administration of azithromycin at 6-month intervals than with one round of mass administration of azithromycin followed by two rounds of targeted treatment. Monitoring for the emergence and spread of antimicrobial resistance is needed. (Funded by Fundació "la Caixa" and others; ClinicalTrials.gov number, NCT03490123.).

MeSH
antibakteriální látky aplikace a dávkování MeSH
azithromycin aplikace a dávkování MeSH
bakteriální léková rezistence MeSH
dítě MeSH
frambézie farmakoterapie epidemiologie MeSH
Haemophilus ducreyi izolace a purifikace MeSH
kojenec MeSH
kožní vředy mikrobiologie MeSH
lidé MeSH
masová profylaxe * MeSH
mladiství MeSH
polymerázová řetězová reakce MeSH
předškolní dítě MeSH
prevalence MeSH
Treponema izolace a purifikace MeSH
Check Tag
dítě MeSH
kojenec MeSH
lidé MeSH
mladiství MeSH
mužské pohlaví MeSH
předškolní dítě MeSH
ženské pohlaví MeSH
Publikační typ
časopisecké články MeSH
klinické zkoušky, fáze III MeSH
multicentrická studie MeSH
práce podpořená grantem MeSH
randomizované kontrolované studie MeSH
Geografické názvy
Papua Nová Guinea MeSH

Článek

Kapavka v rodině

Bížová, Beatrice
Autor Autorita Univerzita Karlova, 2. lékařská fakulta a Fakultní nemocnice Bulovka, Dermatovenerologická klinika

Česká dermatovenerologie. 2021 ; 11 (2) : 55-56.

ISSN 1805-0611
Medvik
Zdroj

MeSH
azithromycin aplikace a dávkování terapeutické užití MeSH
ceftriaxon aplikace a dávkování terapeutické užití MeSH
Chlamydia trachomatis patogenita MeSH
dítě MeSH
dospělí MeSH
faryngitida MeSH
gonorea * diagnóza farmakoterapie přenos MeSH
lidé MeSH
polymerázová řetězová reakce MeSH
předškolní dítě MeSH
přenos infekční nemoci MeSH
sexuálně přenosné nemoci diagnóza farmakoterapie přenos MeSH
uretritida MeSH
vaginitida MeSH
Check Tag
dítě MeSH
dospělí MeSH
lidé MeSH
předškolní dítě MeSH
ženské pohlaví MeSH
Publikační typ
kazuistiky MeSH

Článek

Antibiotická terapie sexuálně přenosných infekcí v éře antibiotického stewardshipu

Adámková, Václava
Autor Autorita ORCID Univerzita Karlova, 1. lékařská fakulta a Všeobecná fakultní nemocnice v Praze, Klinická mikrobiologie a ATB centrum

Česká dermatovenerologie. 2021 ; 11 (2) : 23-29.

ISSN 1805-0611
Medvik
Zdroj

Kapitola

Aktinomykóza bérce

Pitříková, Gabriela
Autor Pitříková, Gabriela Kožní oddělení LF OU a FN, Ostrava

Kazuistiky z dermatologie. 2021 ; () : 100-103.

ISBN 978-80-7345-700-6
Medvik
Zdroj

MeSH
aktinomykóza * diagnóza farmakoterapie mikrobiologie patologie MeSH
antibakteriální látky aplikace a dávkování MeSH
azithromycin aplikace a dávkování MeSH
bérec * patologie MeSH
diferenciální diagnóza MeSH
dospělí MeSH
histologické techniky MeSH
kombinace amoxicilinu a kyseliny klavulanové aplikace a dávkování MeSH
lidé MeSH
neúspěšná terapie MeSH
peniciliny aplikace a dávkování MeSH
výsledek terapie MeSH
vzácné nemoci diagnóza farmakoterapie mikrobiologie patologie MeSH
Check Tag
dospělí MeSH
lidé MeSH
ženské pohlaví MeSH
Publikační typ
kazuistiky MeSH

Článek online

Gentamicin 240 mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of rectal and pharyngeal gonorrhoea: a randomized controlled trial

Clinical microbiology and infection. 2020 ; 26 (2) : 207-212. [pub] 20190814

Clin Microbiol Infect
ISSN 1469-0691
Medvik
Zdroj

OBJECTIVES: The aim was to evaluate the efficacy and tolerability of gentamicin 240 mg plus azithromycin 2 g for treatment of uncomplicated rectal and pharyngeal gonorrhoea compared to ceftriaxone 500 mg plus azithromycin 2 g, the recommended European first-line gonorrhoea treatment. METHODS: A non-inferiority, open-label, single-centre randomized controlled trial was conducted in Prague, Czech Republic. Patients, 18-75 years of age, diagnosed with uncomplicated rectal or pharyngeal gonorrhoea by nucleic acid amplification test (NAAT) were randomized to treatment with gentamicin 240 mg intramuscularly plus azithromycin 2 g orally or ceftriaxone 500 g intramuscularly plus azithromycin 2 g orally. The primary outcome was negative culture and negative NAAT, i.e. 1 week and 3 weeks, respectively, after treatment. RESULTS: Both clinical cure and microbiological clearance was achieved by 100% (95% CI 0.95-1.00) of patients in the gentamicin/azithromycin arm (n = 72; 40 rectal, 17 pharyngeal and 15 rectal+pharyngeal infections both localizations) and 100% (95% CI 0.95-1.00) in ceftriaxone/azithromycin arm (n = 71; 38 rectal, 14 pharyngeal and 19 rectal+pharyngeal infections). The absolute difference between the two arms was 0.0% (CI95% -5.1 to 5.1), thus less than the pre-specified margin of 7%. Administration of gentamicin was not more painful than ceftriaxone according to the visual analogue scale (1.8 vs. 3.4; p <0.001). Gastrointestinal adverse events were similar in the ceftriaxone arm (33/71, 46.5%) and the gentamicin arm (29/72, 40.3%), and overall in most (52/62, 83.9%) cases they were mild. CONCLUSIONS: Gentamicin 240 mg plus azithromycin 2 g is an effective alternative for treatment of extragenital gonorrhoea.

Článek online

Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)-protocol of randomised controlled trial AZIQUINE-ICU

Trials. 2020 ; 21 (1) : 631. [pub] 20200708

ISSN 1745-6215
Medvik
Zdroj

BACKGROUND: Novel coronavirus SARS-CoV-2 is known to be susceptible in vitro to exposure to hydroxychloroquine and its effect has been found to be potentiated by azithromycin. We hypothesise that early administration of hydroxychloroquine alone or in combination with azithromycin can prevent respiratory deterioration in patients admitted to intensive care due to rapidly progressive COVID-19 infection. METHODS: Design: Prospective, multi-centre, double-blind, randomised, controlled trial (RCT). PARTICIPANTS: Adult (> 18 years) within 24 h of admission to the intensive care unit with proven or suspected COVID-19 infection, whether or not mechanically ventilated. Exclusion criteria include duration symptoms of febrile disease for ≥ 1 week, treatment limitations in place or moribund patients, allergy or intolerance of any study treatment, and pregnancy. INTERVENTIONS: Patients will be randomised in 1:1:1 ratio to receive Hydroxychloroquine 800 mg orally in two doses followed by 400 mg daily in two doses and azithromycin 500 mg orally in one dose followed by 250 mg in one dose for a total of 5 days (HC-A group) or hydroxychloroquine + placebo (HC group) or placebo + placebo (C-group) in addition to the best standard of care, which may evolve during the trial period but will not differ between groups. Primary outcome is the composite percentage of patients alive and not on end-of-life pathway who are free of mechanical ventilation at day 14. SECONDARY OUTCOMES: The percentage of patients who were prevented from needing intubation until day 14, ICU length of stay, and mortality (in hospital) at day 28 and 90. DISCUSSION: Although both investigational drugs are often administered off label to patients with severe COVID-19, at present, there is no data from RCTs on their safety and efficacy. In vitro and observational trial suggests their potential to limit viral replication and the damage to lungs as the most common reason for ICU admission. Therefore, patients most likely to benefit from the treatment are those with severe but early disease. This trial is designed and powered to investigate whether the treatment in this cohort of patients leads to improved clinical patient-centred outcomes, such as mechanical ventilation-free survival. TRIAL REGISTRATION: Clinical trials.gov: NCT04339816 (Registered on 9 April 2020, amended on 22 June 2020); Eudra CT number: 2020-001456-18 (Registered on 29 March 2020).

MeSH
azithromycin aplikace a dávkování MeSH
Betacoronavirus * MeSH
dvojitá slepá metoda MeSH
hydroxychlorochin aplikace a dávkování MeSH
jednotky intenzivní péče MeSH
kombinovaná farmakoterapie MeSH
koronavirové infekce farmakoterapie mortalita MeSH
lidé MeSH
pandemie MeSH
prospektivní studie MeSH
randomizované kontrolované studie jako téma * MeSH
virová pneumonie farmakoterapie mortalita MeSH
Check Tag
lidé MeSH
Publikační typ
časopisecké články MeSH
multicentrická studie MeSH
protokol klinické studie MeSH

Článek online

Ulcus molle (měkký vřed) – exotická realita
[Ulcus mulle (chancroid) - exotic reality]

Zákoucká, Hana
Autor Autorita Oddělení sexuálně přenosných infekcí, CEM-SZÚ, Praha

Zprávy Centra epidemiologie a mikrobiologie (2011, Print). 2018 ; 27 (5) : 115-117.

ISSN 1804-8668
Medvik
Zdroj

Výskyt sexuálně přenosných infekcí (STI) je v současnosti naprosto běžným jevem. Některé byly v moderní době dlouho vázány na endemické oblasti (obvykle tropy a subtropy). V ČR k takovým exotickým infekcím patří ulcus molle. Jde o diagnosticky náročné onemocnění s možností výhodně využít multiplexního PCR testu.

Sexually transmitted infections are commonplace today. In the 20th century, some of them used to be endemic in tropical and subtropical areas. In the Czech Republic, an exotic infection of this kind is ulcus molle. The diagnosis of this rare STI is demanding, and a multiplex PCR assay can be a helpful diagnostic tool.

MeSH
azithromycin aplikace a dávkování farmakologie terapeutické užití MeSH
černoši MeSH
diferenciální diagnóza MeSH
kultivační techniky metody MeSH
lidé MeSH
měkký vřed * diagnóza epidemiologie farmakoterapie MeSH
výsledek terapie MeSH
Check Tag
lidé MeSH
mužské pohlaví MeSH
Publikační typ
kazuistiky MeSH

Článek

First reported case of chancroid in the Czech Republic

International journal of STD & AIDS. 2018 ; 29 (11) : 1127-1129. [pub] 20180511

Int J STD AIDS
ISSN 1758-1052
Medvik
Zdroj

We describe the first case of chancroid seen in the Czech Republic, diagnosed in a 40-year-old heterosexual HIV-positive man. Despite genital localization of the ulcer, the transmission of Haemophilus ducreyi infection in our patient remains unclear, as he denied having sexual intercourse and he did not travel outside the Czech Republic for several months before the ulcer appeared. The correct diagnosis has been revealed by a multiplex nucleic acid amplification test. Physicians in countries in the eastern and central Europe region should be aware that chancroid can occur in their patients.